TY  - JOUR
AU  - Cattrini, Carlo
AU  - Caffo, Orazio
AU  - De-Giorgi, Ugo
AU  - Mennitto, Alessia
AU  - Gennari, Alessandra
AU  - Olmos, David
AU  - Castro, Elena
PY  - 2022
DO  - 10.3390/cancers14071792
SN  - 2072-6694
UR  - http://hdl.handle.net/10668/20884
T2  - Cancers
AB  - Nonmetastatic castration-resistant prostate cancer (nmCRPC) represents a condition in which patients with prostate cancer show biochemical progression during treatment with androgen-deprivation therapy (ADT) without signs of radiographic progression...
LA  - en
PB  - MDPI
KW  - PSMA-PET
KW  - Androgen-receptor signaling inhibitors
KW  - Apalutamide
KW  - Conventional imaging
KW  - Darolutamide
KW  - Enzalutamide
KW  - nmCRPC
KW  - Nonmetastatic castration-resistant prostate cancer
KW  - Androgens
KW  - Prostate
KW  - Prostate-Specific Antigen
KW  - Prostatic Neoplasms, Castration-Resistant
KW  - Standard of Care
KW  - Positron-Emission Tomography
TI  - Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
TY  - research article
VL  - 14
ER  -